Cart
sales@molnova.com
PARP1/2/TNKS1/2-IN-1
CAS No. 2243453-32-7
PARP1/2/TNKS1/2-IN-1( —— )
Catalog No. M36459 CAS No. 2243453-32-7
PARP1/2/TNKS1/2-IN-1 is a multi-target inhibitor of PARP-1, PARP-2, TNKS1, and TNKS2, with potential anti-tumor activity that induces apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 95 | In Stock |
|
| 10MG | 134 | In Stock |
|
| 25MG | 163 | In Stock |
|
| 50MG | 189 | In Stock |
|
| 100MG | 247 | In Stock |
|
| 200MG | 365 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePARP1/2/TNKS1/2-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionPARP1/2/TNKS1/2-IN-1 is a multi-target inhibitor of PARP-1, PARP-2, TNKS1, and TNKS2, with potential anti-tumor activity that induces apoptosis.
-
DescriptionPARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual PARP-1, PARP-2, TNKS1 and TNKS2 inhibitor with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP | Apoptosis | Wnt/beta-catenin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2243453-32-7
-
Formula Weight634.66
-
Molecular FormulaC35H31FN6O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOC1=CC=C(NC(C2=CC=C(NC(N3CCN(CC3)C(C4=CC(CC5=NNC(C6=C5C=CC=C6)=O)=CC=C4F)=O)=O)C=C2)=O)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xu Y, et al. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy. Eur J Med Chem. 2022 Jul 5;237:114417. ?
molnova catalog
related products
-
PARP-2-IN-3
PARP-2-IN-3 is used as a potent PARP-2 inhibitor (IC50=0.07 μM) with anti-tumor activity that induces apoptosis and necrosis in cancer cells, and can be used for the study of breast cancer.CAS ??128-52-56-8
-
TIQ-A
TIQ-A is a PARP1 inhibitor which involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.
-
Senaparib
Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
